- Home
- PSHG vs ICU Comparison
PSHG vs ICU Comparison
Compare PSHG & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PSHG | ICU |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | Greece | United States |
| Employees | N/A | 17 |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 19.1M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | PSHG | ICU |
|---|---|---|
| Price | $1.80 | $3.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 39.4K | ★ 69.3K |
| Earning Date | 05-26-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $49.57 | $53.00 |
| Revenue Next Year | $2.73 | $50.00 |
| P/E Ratio | $1.59 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.61 | $0.22 |
| 52 Week High | $2.58 | $5.38 |
Technical Indicators
Market Signals| Indicator | PSHG | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 34.66 |
| Support Level | $1.71 | $2.26 |
| Resistance Level | $1.89 | $4.96 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 60.42 | 8.05 |
Price Performance
Historical ComparisonAbout PSHG Performance Shipping Inc.
Performance Shipping Inc is a shipping company. The company is a provider of shipping transportation services through the ownership of tanker vessels. The company's vessels are employed on time charters with liner companies carrying container vessels and cargo along various shipping routes. It owns and operates Aframax and Suezmax tanker vessels.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.